The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study
The aim of this study was to evaluate the effect of upfront combination therapy with ambrisentan and tadalafil on left ventricular (LV) and right ventricular (RV) function in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). LV and RV peak longitudinal and circum...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-02-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045893217748307 |
| _version_ | 1811318512017211392 |
|---|---|
| author | Takahiro Sato Bharath Ambale-Venkatesh Joao A.C. Lima Stefan L. Zimmerman Ryan J. Tedford Tomoki Fujii Olivia L. Hulme Erica H. Pullins Celia P. Corona-Villalobos Roham T. Zamanian Omar A. Minai Reda E. Girgis Kelly Chin Rubina Khair Rachel L. Damico Todd M. Kolb Stephen C. Mathai Paul M. Hassoun |
| author_facet | Takahiro Sato Bharath Ambale-Venkatesh Joao A.C. Lima Stefan L. Zimmerman Ryan J. Tedford Tomoki Fujii Olivia L. Hulme Erica H. Pullins Celia P. Corona-Villalobos Roham T. Zamanian Omar A. Minai Reda E. Girgis Kelly Chin Rubina Khair Rachel L. Damico Todd M. Kolb Stephen C. Mathai Paul M. Hassoun |
| author_sort | Takahiro Sato |
| collection | DOAJ |
| description | The aim of this study was to evaluate the effect of upfront combination therapy with ambrisentan and tadalafil on left ventricular (LV) and right ventricular (RV) function in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). LV and RV peak longitudinal and circumferential strain and strain rate (SR), which consisted of peak systolic SR (SRs), peak early diastolic SR (SRe), and peak atrial-diastolic SR (SRa) were analyzed using cardiac magnetic resonance imaging (CMRI) data from the recently published ATPAHSS-O trial (ambrisentan and tadalafil upfront combination therapy in SSc-PAH). Twenty-one patients completed the study protocol. Measures of RV systolic function (RV free wall [RVFW] peak longitudinal strain [pLS], RVFW peak longitudinal SRs [pLSRs]) and RV diastolic function (RVFW peak longitudinal SRa [pLSRa], RVFW peak circumferential SRe) were improved after treatment. LV systolic function (LV peak global longitudinal strain [pGLS]) and diastolic function (LV peak global longitudinal SRe [pGLSRe]) were also significantly improved at follow-up. Increased 6-min walk distance was significantly correlated with RVFW pLS and pLSRs, while the decrease in N-terminal pro-brain natriuretic peptide was correlated with LV pGLS. Increased cardiac index was associated with improved LV pGLSRe, and reduction in mean right atrial pressure was correlated with improved RVFW pLS and pLSRa. Combination therapy was associated with a significant improvement in both RV and LV function as assessed by CMR-derived strain and SR. Importantly, the improvement in RV and LV strain and SR correlated with improvements in known prognostic markers of PAH. (Approved by clinicaltrials.gov [NCT01042158] before patient recruitment.) |
| first_indexed | 2024-04-13T12:27:14Z |
| format | Article |
| id | doaj.art-b9b06cd443fb42ed937364be459d940f |
| institution | Directory Open Access Journal |
| issn | 2045-8940 |
| language | English |
| last_indexed | 2024-04-13T12:27:14Z |
| publishDate | 2018-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj.art-b9b06cd443fb42ed937364be459d940f2022-12-22T02:46:59ZengWileyPulmonary Circulation2045-89402018-02-01810.1177/2045893217748307The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking studyTakahiro Sato0Bharath Ambale-Venkatesh1Joao A.C. Lima2Stefan L. Zimmerman3Ryan J. Tedford4Tomoki Fujii5Olivia L. Hulme6Erica H. Pullins7Celia P. Corona-Villalobos8Roham T. Zamanian9Omar A. Minai10Reda E. Girgis11Kelly Chin12Rubina Khair13Rachel L. Damico14Todd M. Kolb15Stephen C. Mathai16Paul M. Hassoun17Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADepartment of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Pulmonary & Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USADivision of Pulmonary and Critical Care Medicine, The Cleveland Clinic, Cleveland, OH, USADivision of Pulmonary Medicine, Spectrum Health/Michigan State University, Grand Rapids, MI, USADivision of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USADivision of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USAThe aim of this study was to evaluate the effect of upfront combination therapy with ambrisentan and tadalafil on left ventricular (LV) and right ventricular (RV) function in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). LV and RV peak longitudinal and circumferential strain and strain rate (SR), which consisted of peak systolic SR (SRs), peak early diastolic SR (SRe), and peak atrial-diastolic SR (SRa) were analyzed using cardiac magnetic resonance imaging (CMRI) data from the recently published ATPAHSS-O trial (ambrisentan and tadalafil upfront combination therapy in SSc-PAH). Twenty-one patients completed the study protocol. Measures of RV systolic function (RV free wall [RVFW] peak longitudinal strain [pLS], RVFW peak longitudinal SRs [pLSRs]) and RV diastolic function (RVFW peak longitudinal SRa [pLSRa], RVFW peak circumferential SRe) were improved after treatment. LV systolic function (LV peak global longitudinal strain [pGLS]) and diastolic function (LV peak global longitudinal SRe [pGLSRe]) were also significantly improved at follow-up. Increased 6-min walk distance was significantly correlated with RVFW pLS and pLSRs, while the decrease in N-terminal pro-brain natriuretic peptide was correlated with LV pGLS. Increased cardiac index was associated with improved LV pGLSRe, and reduction in mean right atrial pressure was correlated with improved RVFW pLS and pLSRa. Combination therapy was associated with a significant improvement in both RV and LV function as assessed by CMR-derived strain and SR. Importantly, the improvement in RV and LV strain and SR correlated with improvements in known prognostic markers of PAH. (Approved by clinicaltrials.gov [NCT01042158] before patient recruitment.)https://doi.org/10.1177/2045893217748307 |
| spellingShingle | Takahiro Sato Bharath Ambale-Venkatesh Joao A.C. Lima Stefan L. Zimmerman Ryan J. Tedford Tomoki Fujii Olivia L. Hulme Erica H. Pullins Celia P. Corona-Villalobos Roham T. Zamanian Omar A. Minai Reda E. Girgis Kelly Chin Rubina Khair Rachel L. Damico Todd M. Kolb Stephen C. Mathai Paul M. Hassoun The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study Pulmonary Circulation |
| title | The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study |
| title_full | The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study |
| title_fullStr | The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study |
| title_full_unstemmed | The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study |
| title_short | The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study |
| title_sort | impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients cardiac magnetic resonance feature tracking study |
| url | https://doi.org/10.1177/2045893217748307 |
| work_keys_str_mv | AT takahirosato theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT bharathambalevenkatesh theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT joaoaclima theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT stefanlzimmerman theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT ryanjtedford theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT tomokifujii theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT olivialhulme theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT ericahpullins theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT celiapcoronavillalobos theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT rohamtzamanian theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT omaraminai theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT redaegirgis theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT kellychin theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT rubinakhair theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT rachelldamico theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT toddmkolb theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT stephencmathai theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT paulmhassoun theimpactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT takahirosato impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT bharathambalevenkatesh impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT joaoaclima impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT stefanlzimmerman impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT ryanjtedford impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT tomokifujii impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT olivialhulme impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT ericahpullins impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT celiapcoronavillalobos impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT rohamtzamanian impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT omaraminai impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT redaegirgis impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT kellychin impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT rubinakhair impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT rachelldamico impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT toddmkolb impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT stephencmathai impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy AT paulmhassoun impactofambrisentanandtadalafilupfrontcombinationtherapyoncardiacfunctioninsclerodermaassociatedpulmonaryarterialhypertensionpatientscardiacmagneticresonancefeaturetrackingstudy |